LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Strona główna・Stock List・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Closed

SectorHealthcare

13.31 -2.2

Buy Sell

Overview

Share price change

24h

Current

Min

13.1

Max

13.83

Key metrics
By Trading Economics
Income	6.8M -12M
Sales	-1.5M 17M
Profit margin	-64.131
Employees	120
EBITDA	-16M -24M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+42.43% upside

Dividends
By Dow Jones
Next Earnings	7 sie 2026

Market Stats
By TradingEconomics
Market Cap	27M 449M
Previous open	15.51
Previous close	13.31

News Sentiment

By Acuity

75%

25%

319 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

5.04 / 5.44 Support & Resistance

ENANTA PHARMACEUTICALS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 maj 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 maj 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 maj 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 maj 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 maj 2026, 16:02 UTC

Earnings

Major Market Movers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 maj 2026, 14:55 UTC

Major Market Movers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 maj 2026, 14:43 UTC

Major Market Movers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 maj 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 maj 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 maj 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 maj 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 maj 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 maj 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 maj 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 maj 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 maj 2026, 16:24 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 maj 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 maj 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 maj 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 maj 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 maj 2026, 15:20 UTC

Earnings

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 maj 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

42.43% upside

12 Months Forecast

Average 19.67 USD 42.43%

High 20 USD

Low 19 USD

Based on 3 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to ENANTA PHARMACEUTICALS INC - Dist in the past 3 months.

Technical Score

By Trading Central

5.04 / 5.44Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

319 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.